Commitments and Contingencies	6 Months Ended
Jun. 30, 2026
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies There are no material commitments and contingencies as of June 30, 2026 and December 31, 2025. We are currently involved in, and may in the future become involved in, legal proceedings, claims, investigations and regulatory inquiries in the ordinary course of our business, including medical malpractice claims. These claims or proceedings can involve various types of parties, including governments, regulators, competitors, customers, partners, suppliers, service providers, licensees, licensors, employees, or stockholders, among others. Although the results of these legal proceedings, claims, investigations and inquiries cannot be predicted with certainty, we do not believe that the final outcome of any matters that we are currently involved in are reasonably likely to have a material adverse effect on our business, financial condition or results of operations. Regardless of final outcomes, however, any such proceedings, claims, inquiries and investigations may nonetheless impose a significant burden on management and employees and be costly to manage and defend, with potentially unfavorable preliminary or interim rulings. The Company records liabilities for its estimates of probable costs resulting from legal and regulatory matters where appropriate. Estimates of costs resulting from legal and regulatory matters involving the Company are inherently difficult to predict, particularly where the matters: may involve indeterminate claims for monetary damages or may involve fines, penalties or civil damages; involve an uncertain number of potential claimants or regulatory bodies; are in the early stages of the proceedings; or could result in a change in compliance practices. On March 24, 2026, after we made a voluntary disclosure to various federal and state authorities, the Company received a “Request for Information or Assistance” from the Department of Health and Human Services’ Office of Inspector General (“OIG”). The inquiry pertains to a single obstetric and gynecological Affiliated Practice that was formerly in Privia’s Mid-Atlantic service area, and whether that practice procured and implanted medical devices for a limited cohort of its patients without complying with applicable regulatory requirements. The Company is not aware of similar conduct at its other Affiliated Practices. The Company is cooperating with OIG’s request for information and is coordinating its response with the U.S. Department of Justice (“DOJ”) and the Commonwealth of Virginia’s Office of the Attorney General. While the Company does not currently believe that this matter is reasonably likely to have a material adverse effect on its business, financial condition or results of operations, the Company can provide no assurance as to the scope and outcome of this inquiry given its procedural status, including the ultimate extent of governmental interest in the matter.

We are currently involved in, and may in the future become involved in, legal proceedings, claims, investigations and regulatory inquiries in the ordinary course of our business, including medical malpractice claims. These claims or proceedings can involve various types of parties, including governments, regulators, competitors, customers, partners, suppliers, service providers, licensees, licensors, employees, or stockholders, among others. Although the results of these legal proceedings, claims, investigations and inquiries cannot be predicted with certainty, we do not believe that the final outcome of any matters that we are currently involved in are reasonably likely to have a material adverse effect on our business, financial condition or results of operations. Regardless of final outcomes, however, any such proceedings, claims, inquiries and investigations may nonetheless impose a significant burden on management and employees and be costly to manage and defend, with potentially unfavorable preliminary or interim rulings.

The Company records liabilities for its estimates of probable costs resulting from legal and regulatory matters where appropriate. Estimates of costs resulting from legal and regulatory matters involving the Company are inherently difficult to predict, particularly where the matters: may involve indeterminate claims for monetary damages or may involve fines, penalties or civil damages; involve an uncertain number of potential claimants or regulatory bodies; are in the early stages of the proceedings; or could result in a change in compliance practices.

On March 24, 2026, after we made a voluntary disclosure to various federal and state authorities, the Company received a “Request for Information or Assistance” from the Department of Health and Human Services’ Office of Inspector General (“OIG”). The inquiry pertains to a single obstetric and gynecological Affiliated Practice that was formerly in Privia’s Mid-Atlantic service area, and whether that practice procured and implanted medical devices for a limited cohort of its patients without complying with applicable regulatory requirements. The Company is not aware of similar conduct at its other Affiliated Practices.

The Company is cooperating with OIG’s request for information and is coordinating its response with the U.S. Department of Justice (“DOJ”) and the Commonwealth of Virginia’s Office of the Attorney General. While the Company does not currently believe that this matter is reasonably likely to have a material adverse effect on its business, financial condition or results of operations, the Company can provide no assurance as to the scope and outcome of this inquiry given its procedural status, including the ultimate extent of governmental interest in the matter.